Publications by authors named "Christophe Boetsch"

Claim this Profile
C
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.
Ignacio Melero, Josep Tabernero, Neeltje Steeghs, Debbie G J Robbrecht, Solange Peters, Christophe Boetsch

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging in vitro Tumor Cell Killing and Cytokine Release to Predict Cytokine Release Syndrome Associated with CD3 T-cell Bispecifics in Oncology: a Retrospective Analysis.
Apolline Lefèvre, Zinnia P Parra-Guillen, Iñaki F Trocóniz, Christophe Boetsch, Nicolas Frances

AAPS J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes.
Jiawen Zhu, Amy Schroeder, Sabine Frank, Christophe Boetsch, Candice Jamois

Clin Pharmacol Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies.
Apolline Lefèvre, Zinnia P Parra-Guillen, Iñaki F Trocóniz, Christophe Boetsch, Nicolas Frances

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.
Valentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, Jean-Pascal Machiels, Miguel F Sanmamed, Christophe Boetsch

Cancer Res Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V Long, Miguel F Sanmamed, Christophe Boetsch

Cancer Res Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy.
Prathap Nagaraja Shastri, Nirav Shah, Martin Lechmann, Hardik Mody, Marc W Retter, Christophe Boetsch

Clin Pharmacol Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht, Loic Verlingue, Antoine Italiano, Christophe Boetsch

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
Loic Verlingue, Antoine Italiano, Hans Prenen, Eva Maria Guerra Alia, Diego Tosi, Christophe Boetsch

EBioMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody.
Sara Belli, Maria Amann, Lucy Hutchinson, Laurène Pousse, Afsaneh Abdolzade-Bavil, Christophe Boetsch

Clin Pharmacol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, Morten Mau-Sørensen, Debbie Robbrecht, Christophe Boetsch

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.
Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R Lindsay, Iwona Lugowska, Christophe Boetsch

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Solange Peters, Eric Angevin, Teresa Alonso-Gordoa, Kristoffer Rohrberg, Ignacio Melero, Christophe Boetsch

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Gabrielle Leclercq, Hélène Haegel, Anneliese Schneider, Anna Maria Giusti, Estelle Marrer-Berger, Christophe Boetsch

J Immunother Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD25-T-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Isabelle Solomon, Maria Amann, Anne Goubier, Frederick Arce Vargas, Dimitrios Zervas, Christophe Boetsch

Nat Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Johanna C Bendell, Tamara Sauri, Antonio Cubillo Gracián, Rafael Alvarez, Carlos López-López, Christophe Boetsch

Oncologist· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.
Benjamin Ribba, Christophe Boetsch, Tapan Nayak, Hans Peter Grimm, Jehad Charo

Clin Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, Christophe Massard, Elena Garralda, Christophe Boetsch

Clin Cancer Res· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
Carsten Hofmann, Flavia Pizzagalli, Christophe Boetsch, Daniela Alberati, Larry Ereshefsky

Psychopharmacology (Berl)· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Christophe Boetsch, Neil Parrott, Stephen Fowler, Agnes Poirier, Dominik Hainzl

Clin Pharmacokinet· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin.
Neil Parrott, Dominik Hainzl, Emmanuel Scheubel, Siegfried Krimmer, Christophe Boetsch

AAPS J· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis